Related Experiment Videos
VAD-based regimens as primary treatment for multiple myeloma
R Alexanian1, B Barlogie, S Tucker
1University of Texas, M.D. Anderson Cancer Center, Houston 77030.
American Journal of Hematology
|February 1, 1990
Summary
A VAD-based regimen for multiple myeloma showed a 55% response rate, similar to older treatments. While responses were faster, remission and survival times remained unchanged, suggesting VAD is effective for rapid control in newly diagnosed patients.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Multiple myeloma treatment requires effective regimens for rapid disease control.
- Previous VAD (vincristine, doxorubicin, dexamethasone) regimens showed promise.
Purpose of the Study:
- To evaluate an alternating VCAD-VAD regimen in previously untreated multiple myeloma patients.
- To compare the efficacy of continuous infusion VAD with bolus administration.
Main Methods:
- A total of 175 previously untreated multiple myeloma patients received either VCAD-VAD or VAD.
- VAD involved vincristine and doxorubicin by continuous infusion, with cyclophosphamide and pulse dexamethasone.
Main Results:
- The VAD-based regimens achieved a 55% response rate, comparable to 54% with previous bolus VAD.
- Responses to VAD were more rapid in onset than prior treatments.
- Remission and survival durations were similar across regimens.
Conclusions:
- VAD-based regimens are effective for achieving rapid control in newly diagnosed multiple myeloma.
- Differences in drug sensitivity between myeloma cell types may influence outcomes.
- Continuous infusion VAD offers a viable option for initial multiple myeloma management.